GILEAD SCIENCES INC (GILD)

US3755581036 - Common Stock

77.01  +0.5 (+0.65%)

After market: 76.9992 -0.01 (-0.01%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GILEAD SCIENCES INC

NASDAQ:GILD (7/26/2024, 7:00:01 PM)

After market: 76.9992 -0.01 (-0.01%)

77.01

+0.5 (+0.65%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-3.16%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap95.94B
Shares
PE17.7
Fwd PE10.55
Dividend Yield4.19%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GILD Daily chart

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 18,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. The company is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The firm operates in more than 35 countries.

Company Info

GILEAD SCIENCES INC

333 Lakeside Dr

Foster City CALIFORNIA 94404

P: 16505743000

CEO: Daniel P. O'Day

Employees: 18000

Website: https://www.gilead.com/

GILD News

News Imagea day ago - The Business JournalsGilead Foundation announces HEAL initiative to develop more diverse Bay Area healthcare workforce
News Imagea day ago - Gilead Sciences, Inc.Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
News Image2 days ago - Market News VideoSeptember 6th Options Now Available For Gilead Sciences (GILD)
News Image2 days ago - Gilead Sciences, Inc.Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
News Image2 days ago - The Motley Fool3 Stocks That Can Help You to Get Richer in 2024 and Beyond

Good bargains still abound in the market, and two of the stocks below offer fat dividends as well.

News Image2 days ago - BloombergGilead’s HIV Prevention Drug Isn’t Coming Fast Enough for Activists

Gilead Sciences Inc. is facing pressure to speed up its plans to bring an experimental HIV prevention drug to market after new data further underscored how useful the medicine could be in the fight against AIDS.

GILD Twits

Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example